Loading news...
Nextech Invest increased its stake in Relay Therapeutics by 855,097 shares; the estimated trade value was ~$6.1 million based on average quarterly pricing. Quarter-end position value rose by $19.7 million, reflecting both new share purchases and stock price moves.
The data revealed on Monday that the 400mg BID fed regimen of zovegalisib demonstrated a median progression-free survival (PFS) of 11.1 months in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.
400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Efficacy in patients with kinase and non-kinase domain mutations is similar, with median PFS of 11.2 and 11.0 months, respectively Safety and tolerability data are consistent with 600mg BID fasted data Zovegalisib has received FDA Breakthrough Therapy designation for the Phase 3 ReDiscover-2 trial population CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced data from the Phase 1/2 ReDiscover trial of zovegalisib (RLY-2608) + fulvestrant at the recommended Phase 3 dose of 400mg twice daily (BID) taken with food (fed) in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.
Relay Therapeutics, Inc. (NASDAQ: RLAY - Get Free Report) shares hit a new 52-week high during mid-day trading on Friday after Guggenheim raised their price target on the stock from $15.00 to $22.00. Guggenheim currently has a buy rating on the stock. Relay Therapeutics traded as high as $11.49 and last traded at $10.8950, with a
Relay Therapeutics, Inc. (RLAY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Relay Therapeutics (RLAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Relay Therapeutics, Inc. (RLAY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Relay Therapeutics is approaching a pivotal clinical catalyst with the March 16th zovegalisib Phase 1/2 data readout at ESMO TAT. RLAY's financials show improved operational efficiency, with reduced R&D and G&A expenses, but the company remains in a high-investment, pre-commercial phase. Breakthrough Therapy Designation for zovegalisib in metastatic breast cancer signals strong regulatory momentum and potential differentiation in a large, underserved market.
Shares of Relay Therapeutics, Inc. (NASDAQ: RLAY - Get Free Report) hit a new 52-week high on Friday after the company announced better than expected quarterly earnings. The stock traded as high as $10.99 and last traded at $11.2970, with a volume of 1751195 shares traded. The stock had previously closed at $9.16. The company reported
Casdin Capital bought 1,662,193 shares of Relay Therapeutics; the estimated trade size was $11.86 million. Meanwhile, the quarter-end position value rose by $50.81 million, reflecting both trading and price appreciation.
Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.45 per share a year ago.
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced in 2026 Initial Phase 1/2 data of zovegalisib + fulvestrant at 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO TAT on March 16, 2026 Approximately $555 million in cash, cash equivalents and investments at end of Q4 2025 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today reported fourth quarter and full year 2025 financial results and 2026 guidance.
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in March:
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report fourth quarter and full year 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 26, 2026.
Donald Bergstrom sold 21,581 shares over Jan. 27 and Jan. 28, 2026, generating a total value of approximately $166,700 at a weighted average price around $7.72 per share. This transaction reduced his direct holdings by 4.89%, leaving him with 420,047 directly held shares post-sale.
/PRNewswire/ -- USANewsGroup.com News Commentary - The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m.
Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO Targeted Anticancer Therapies Congress on March 16 CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to zovegalisib (RLY-2608) in combination with fulvestrant for the treatment of adults with PIK3CA mutant, hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
Relay Therapeutics is upgraded to Outperform with a $14 price target, driven by optimism for zovegalisib in PIK3CA-mutant HR+/HER2- metastatic breast cancer. Zovegalisib's mutant-selective PI3Kα inhibition offers a differentiated safety and efficacy profile versus broader PI3K inhibitors, targeting a large, underserved patient population. RLAY's $596M cash position funds operations into 2029, supporting ongoing pivotal Phase 3 and expansion studies across oncology and vascular malformations.
Relay Therapeutics shared interim data for zovegalisib at SABCS 2025, showing consistent efficacy in breast cancer patients.